Classification of Non-Hodgkin's Lymphomas

Bennett, M.H.; Farrer-Brown, G; Henry, Kristin; Jelliffe, A.M.; Gérard-Marchant, R; Hamlin, Iris M. E.; Lennert, K.; Rilke, F; Stansfeld, A. G.; Unnik, J. A. M. van

doi:10.1016/s0140-6736(74)91786-3

Cited by 291 publications

(38 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The series consisted of 175 patients with primary gastrointestinal (GI) NHL, namely those whose main presenting feature was related to the GI tract or in which the predominant lesion was clearly in the GI tract, who were entered into BNLI studies between 1974 and 1988 (Bennett et al, 1974) and the Working Formulation (WF) (NCI., 1982). Especial emphasis was placed on the identification of lymphomas of the intestine with histological features typical of the entity described by Isaacson and Wright (1978) as a malignant histiocytosis of the intestine (MHI), and later demonstrated to be T-cell lymphoma (Isaacson et al, 1985), termed by some as enteropathy associated T-cell lymphoma.…”

Section: Methodsmentioning

confidence: 99%

Primary gastrointestinal non-Hodgkin's lymphoma: a review of 175 British National Lymphoma Investigation cases

Morton¹,

Leyland²,

Hudson³

et al. 1993

Br J Cancer

121

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Primary gastrointestinal non-Hodgkin's lymphoma: a review of 175 British National Lymphoma Investigation cases

Morton¹,

Leyland²,

Hudson³

et al. 1993

Br J Cancer

121

View full text Add to dashboard Cite

“…MCL was included in the Revised European-American Lymphoma (REAL) classification system recently proposed by the International Lymphoma Group in 1994 (Harris et al, 1994). This lymphoma is equivalent to previously recognized entities such as centrocytic lymphoma in the Kiel classification (Lennert, 1978), intermediately differentiated lymphocytic lymphoma by some American groups (Berard et al, 1978), diffuse small cleaved cell lymphomas in the Working Formulation (Rosenberg, 1982) or diffuse lymphocytic lymphoma in the BNLI classification (Bennett, 1974). Patients are usually middle-aged to elderly males who present with extensive disease and B symptoms, extranodal organ involvement and marked splenomegaly (Vandenberghe et al, 1991;Swerdlow et al, 1983;Zucca et al, 1995;Pittaluga et al, 1995).…”

mentioning

confidence: 99%

The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non‐intensive therapy by the British National Lymphoma Investigation Group

et al. 1997

View full text Add to dashboard Cite

Mantle cell lymphoma (MCL) was first described as a distinct biological entity on the basis of its association with the t(11;14)(q13;q32) resulting in over‐expression of the cyclin D1 gene. Recognition of the morphological, immunophenotypic and clinical characteristics of MCL has enabled the accurate diagnosis of this entity and appreciation of its poor prognosis. Most published series of patients with MCL have used anthracycline‐containing regimens. In contrast the British National Lymphoma Investigation (BNLI) group have treated 65 patients with MCL with non‐intensive ‘low‐grade lymphoma’ therapy. The median overall survival of 57 months and progression‐free survival of 24 months compares favourably with the more intensively treated series. Although the disease was generally more aggressive than other low‐grade lymphomas, some patients were asymptomatic and had indolent disease. When compared to 1853 patients with non‐MCL low‐grade lymphomas entered on the BNLI database, patients were found on average to be older (P = 0.02), to have more extra‐nodal disease (P < 0.00001), and a higher proportion to have a raised ESR (P = 0.02) and a low serum albumin (P = 0.002). Multivariate analysis of significant prognostic markers in all BNLI low‐grade lymphomas failed to identify MCL as an independent prognostic factor.

show abstract

“…This kind of analysis has more recently been applied to malignant lymphomas, the solid tumours of the immune system (Smith et al, 1973;Jaffe et at., 1974;Huber et al, 1974;Aisenberg and Long, 1975;Leech et al, 1975) Brouet, Labaume andSeligmann, 1975). The classification of these diseases is currently receiving a critical re-analysis in the light of current immunological understanding of the function of the components of the immune system (Gerard-Marchant et al, 1974;Lukes and Collins, 1975;Bennett et at., 1974). We have investigated a group of untreated non-Hodgkin's lymphomas using a panel of lymphocyte markers, including surface and intracellular immunoglobulin, Fcy and C3 receptors and sheep erythrocyte (E) receptors.…”

mentioning

confidence: 99%

Lymphocyte markers in non-Hodgkin's lymphomas

Payne¹,

Smith²,

Jones³

et al. 1977

Br J Cancer

View full text Add to dashboard Cite

Summary.-The lymphocyte marker pattern of non-Hodgkin's lymphoma cells was related to current concepts of lymphoma classification. In a series of 28 lymphomas, lymphocyte markers indicated that 2 were of histiocytic origin, 2 were unclassifiable, none were derived from T cells and the remainder were B -cell neoplasms. The immunoglobulin heavy chain associated with the B-cell tumours was y in one case, af in one case but was ,-in the majority of cases, reflecting the predominance of this heavy chain, together with 8 chains, on normal lymph node lymphocytes in man. 8 chains accompanied ,u chains on the tumour cells i!1 6/17 lymphomas in which anti-8 staining was performed. 8 chains were not found on any lymphomas other than well differentiated diffuse lymphocytic types. There was evidence of a reduction in surface immunoglobulin, Fcy and C3 receptors on undifferentiated lymphoma cells. T lymphocytes of normal morphology were present in all lymphomas except one, and were more numerous in follicular lymphomas than in diffuse tumours.

show abstract

Classification of Non-Hodgkin's Lymphomas

Cited by 291 publications

References 5 publications

Primary gastrointestinal non-Hodgkin's lymphoma: a review of 175 British National Lymphoma Investigation cases

Primary gastrointestinal non-Hodgkin's lymphoma: a review of 175 British National Lymphoma Investigation cases

The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non‐intensive therapy by the British National Lymphoma Investigation Group

Lymphocyte markers in non-Hodgkin's lymphomas

Contact Info

Product

Resources

About